Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company securing its first national patent for POLB-001 targeting cancer immunotherapy-induced cytokine release syndrome (CRS).
Skillington explained that the patent, granted by IP Australia, covers the use of p38 MAPK inhibitors, including POLB-001, to prevent and treat CRS. He highlighted that the protection is broad and supported by proprietary data generated by the company, following a thorough examination process. The patent marks an important milestone as Poolbeg continues expanding into oncology, building on earlier filings made in the UK and through international patent cooperation frameworks.
He noted the timing aligns well with upcoming clinical developments, with interim data from its clinical trial expected in the summer. Skillington said: “The timing of this is absolutely perfect,” emphasising how the patent strengthens the company’s position as it advances the programme.
The discussion also outlined why intellectual property is critical for large pharmaceutical partners. Skillington explained that strong patent protection provides exclusivity and reduces uncertainty, which is essential given the significant investment required to bring drugs to market. He added that Poolbeg aims to leverage this growing IP portfolio to support future partnering opportunities.
Looking ahead, the company plans to expand patent coverage into additional jurisdictions while progressing its clinical programme and delivering near-term milestones.
For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update.
#PoolbegPharma #POLB001 #BiotechNews #PharmaInnovation #CancerImmunotherapy #CRS #DrugDevelopment #ClinicalTrials #BiotechInvesting #IntellectualProperty #PharmaPartnerships #LifeSciences #HealthcareInnovation #OncologyResearch #BiotechStocks
